Stock Events

AMGEN 

€252.8
37
+€2.4+0.96% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
146.84B
P/E Ratio
21.48
Dividend Yield
3.16%
Dividend
7.99

Upcoming

Dividends

3.16%Dividend Yield
Dec 23
€1.96
Sep 23
€1.96
Jun 23
€1.97
Mar 23
€1.98
Dec 22
€1.87

Earnings

29JanExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Next
3.85
4.23
4.62
5
Expected EPS
4.61
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AMG.XETRA. It's not an investment recommendation.

Analyst Ratings

275.73Average Price Target
The highest estimate is €320.
From 15 ratings within the last 6 months. This is not an investment recommendation.
Buy
47%
Hold
47%
Sell
7%

About

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; and Datos Health. It also has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Show more...
CEO
Mr. Robert A. Bradway
Employees
24300
Country
US
ISIN
US0311621009
WKN
000867900

Listings